Drug Type Autologous CAR-T |
Synonyms NKG2D chimeric antigen receptor-T cells, KD 025, KD-025 |
Target |
Action antagonists |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | China | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 17 May 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 17 May 2022 | |
NKG2DL Positive Solid Tumors | Phase 1 | China | 17 May 2022 | |
NKG2DL Positive Solid Tumors | Phase 1 | China | 17 May 2022 |
Phase 2 | 54 | jpgjdjkyvz(kwzdhncqrp) = Commonly reported AEs were URTI, AST/ALT elevations, fatigue, nausea and diarrhea. jitkxcikct (rvusgvdcye ) View more | Positive | 15 Jun 2019 | |||